Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry.

Grounds RM, Seebach C, Knothe C, Paluszkiewicz P, Smith TS, Kasal E, Lecumberri R, Urbanec R, Haas T, Wujtewicz M, Rehorkova D, Pelichovska M, Lange M, Uranga M, Bosman R, Rommes JH, Koscielny J.

J Intensive Care Med. 2006 Jan-Feb;21(1):27-39.

PMID:
16698742
2.

[Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].

Grinţescu I, Tulbure D, Mirea L.

Chirurgia (Bucur). 2006 Nov-Dec;101(6):615-24. Romanian.

PMID:
17283837
3.

Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series.

Alsayegh F, Fakeir A, Alhumood S, Abdumalek K, Matar H, Samaul I, Nampoory N, Kabalawi H, Mousa SA.

Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):225-32. Epub 2007 Dec 26.

PMID:
18160562
4.

Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.

Felfernig M; European rFVIIa Trauma Study Group.

J R Army Med Corps. 2007 Mar;153(1):32-9.

PMID:
17575875
5.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
6.

Recombinant activated coagulation factor VII and bleeding trauma patients.

Rizoli SB, Nascimento B Jr, Osman F, Netto FS, Kiss A, Callum J, Brenneman FD, Tremblay L, Tien HC.

J Trauma. 2006 Dec;61(6):1419-25.

PMID:
17159685
7.

The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.

Spinella PC, Perkins JG, McLaughlin DF, Niles SE, Grathwohl KW, Beekley AC, Salinas J, Mehta S, Wade CE, Holcomb JB.

J Trauma. 2008 Feb;64(2):286-93; discussion 293-4. doi: 10.1097/TA.0b013e318162759f.

PMID:
18301188
8.

Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.

Brandsborg S, Sørensen B, Poulsen LH, Ingerslev J.

Blood Coagul Fibrinolysis. 2006 Jun;17(4):241-9.

PMID:
16651865
9.

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Transfusion. 2009 Dec;49 Suppl 5:240S-7S. doi: 10.1111/j.1537-2995.2008.01987.x.

PMID:
19954486
10.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
11.

Pediatric off-label use of recombinant factor VIIa.

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Pediatrics. 2009 Mar;123(3):1066-72. doi: 10.1542/peds.2008-1685.

PMID:
19255041
12.

Use of recombinant activated factor VII in intractable bleeding during pediatric neurosurgical procedures.

Uhrig L, Blanot S, Baugnon T, Orliaguet G, Carli PA, Meyer PG.

Pediatr Crit Care Med. 2007 Nov;8(6):576-9.

PMID:
18062085
13.

Evidence-based Emergency Medicine/Critically Appraised Topic. The efficacy of recombinant activated factor VII in severe trauma.

Nishijima DK, Zehtabchi S.

Ann Emerg Med. 2009 Nov;54(5):737-744.e1. doi: 10.1016/j.annemergmed.2009.01.027. Epub 2009 Mar 14. Review.

PMID:
19285753
14.

The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.

Wilson SJ, Bellamy MC, Giannoudis PV.

Expert Opin Drug Saf. 2005 May;4(3):557-70. Review.

PMID:
15934860
15.

"Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage.

Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M.

J Trauma. 2005 Jul;59(1):150-4.

PMID:
16096555
16.

Global differences in causes, management, and survival after severe trauma: the recombinant activated factor VII phase 3 trauma trial.

Christensen MC, Parr M, Tortella BJ, Malmgren J, Morris S, Rice T, Holcomb JB; CONTROL Study Group.

J Trauma. 2010 Aug;69(2):344-52. doi: 10.1097/TA.0b013e3181e74c69.

PMID:
20699743
17.

Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.

Perkins JG, Schreiber MA, Wade CE, Holcomb JB.

J Trauma. 2007 May;62(5):1095-9; discussion 1099-101.

PMID:
17495707
18.

Factor VIIa for correction of traumatic coagulopathy.

Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM.

J Trauma. 2004 Oct;57(4):709-18; discussion 718-9.

PMID:
15514523
19.

Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.

Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA; Australian and New Zealand Haemostasis Registry.

Anesth Analg. 2009 Dec;109(6):1908-15. doi: 10.1213/ANE.0b013e3181c039e6.

PMID:
19923520
20.

The use of recombinant factor VIIa for severe intractable bleeding during spine surgery.

Kaw LL Jr, Coimbra R, Potenza BM, Garfin SR, Hoyt DB.

Spine (Phila Pa 1976). 2004 Jun 15;29(12):1384-7; discussion 1388.

PMID:
15187645
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk